Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects
.

@article{Lee2017ComparativePA,
  title={Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects
.},
  author={Heechan Lee and S V Yim and Bo-Hyung Kim and Seunghwan Lee},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2017},
  volume={55 1},
  pages={95-101}
}
BACKGROUND Morniflumate is a nonsteroid anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1, 2 (COX-1, 2). OBJECTIVE This study aimed to compare the pharmacokinetics (PKs) and assess the bioequivalence of two different formulations of morniflumate 350-mg tablets in healthy Korean male subjects. METHODS A randomized, single-dose, two-period… CONTINUE READING